Rat IgG-heavy and light chain cross-adsorbed Antibody

F(ab')2 Goat Polyclonal Conjugate FITC

Antigen Affinity Purified

Catalog No. A110-238F

Lot No. A110-238F-4

APPLICATIONS	IHC, ICC, F, IF
SPECIES REACTIVITY	Rat. Minimum reactivity to human and mouse
ISOTYPE	IgG
AMOUNT	1 ml at 0.5 mg/ml
STORAGE/SHELF LIFE	2 - 8° C / 1 year from date of receipt
PHYSICAL STATE	Liquid
FLUOROPHORE/PROTEIN	4.9
BUFFER	Phosphate Buffered Saline (PBS) containing 0.2% BSA and 0.09% Sodium Azide
ORIGIN	USA
PRODUCTION PROCEDURES	Antiserum was cross adsorbed using human and mouse immunosorbents to remove cross reactive antibodies. The antibody to rat IgG was isolated by affinity chromatography using antigen coupled to agarose beads. F(ab')2 fragments were generated using a pepsin digestion. Fc fragments and whole IgG molecules have been removed. Fragments were conjugated to fluorescein isothiocyanate (FITC). Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG. By immunoelectrophoresis and ELISA this antibody reacts specifically with rat IgG and with light chains common to other rat immunoglobulins. No antibody was detected against non-immunoglobulin serum proteins. Less than 1% cross reactivity to human and mouse IgG was detected. This antibody may cross react with IgG from other species.
APPLICATIONS	Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

Immunohistochemistry	1:50 - 1:500
Immunocytochemistry	1:50 - 1:500
Flow Cytometry	1:50 - 1:200
Immunofluorescence	1:50 - 1:500

APPLICATION NOTES Not all listed applications have been specifically tested by our laboratory.

ADDITIONAL INFO https://www.bethyl.com/product/A110-238F
Use the link above to view SDS, a current list of citations, and other product specific information.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.

Eric McIntush, PhD | Chief Scientific Officer Date: December 3, 2018